. 2013 Jun 6;28(10):1443–1446. doi: 10.1002/mds.25520

Table 1.

Demographic and polysomnographic data of 33 IPD patients and 37 age-matched controls

	Mean ± SD or No. (%)
Variable	IPD patients	Controls	P
Demographic data
Age, y	65.5 ± 11.6	66.7 ± 9.0	0.66^a
Sex: Men/women	12/21	21/16	0.09
Educational level, y	12.2 ± 3.7	12.6 ± 3.5	0.77^b
MMSE score	28.82 ± 1.7	28.78 ± 3.0	0.95^b
BMI, kg/m²	25.3 ± 3.9	27.0 ± 4.0	0.08^b
Hoehn-Yahr stage	2.0 ± 0.5	–	–
PD duration, y	1.9 ± 1.3	–	–
Levodopa dosage, mg	238.3 ± 331.5	–	–
Dopamine agonists, mg^c	1.0 ± 2.0	0.06 ± 0.3	<0.01
Antidepressants	8 (24)	6 (16)	0.40
Sedatives	4 (12)	5 (13)	0.86
Total sleep time, min	308.8 ± 58.0	325.8 ± 63.5	0.24^b
Polysomnographic data
Total sleep time, min	308.8 ± 58.0	325.8 ± 63.5	0.24^b
Sleep latency, min	36.7 ± 27.3	36.3 ± 26.5	0.95^a
Sleep efficiency, %	72.1 ± 15.2	74.4 ± 12.9	0.49^a
NREM sleep stage 2, min	175.2 ± 47.0	176.4 ± 51.8	0.98^d
NREM sleep stage 2, %	43.4 ± 11.4	44.5 ± 13.3	0.61^b
NREM sleep stage 3, min	51.2 ± 45.7	61.9 ± 47.14	0.34^a
NREM sleep stage 3, %	13.6 ± 12.0	14.6 ± 9.2	0.69^a
REM sleep stage, min	43.0 ± 29.6	53.7 ± 25.9	0.09^d
REM sleep stage, %	11.1 ± 7.1	13.6 ± 7.1	0.15^a
Index of apnea/hypopnea/h	2.5 ± 4.9	2.1 ± 3.3	0.71^a
Index of periodic leg movements/h	4.7 ± 14.9	5.8 ± 13.2	0.75^a
REM sleep muscle atonia, %	79.9 ± 30.9	92.7 ± 22.4	0.0497^a
Awakenings/h	6.0 ± 4.0	4.5 ± 3.2	0.10^a
Arousals/h	7.8 ± 4.8	7.9 ± 6.7	0.94^a

Welch analysis of variance.

Mann-Whitney test.

Expressed in pergolide equivalents, with 1 mg of pergolide = 10 mg bromocriptine = 3 mg of ropinirole = 1 mg of pramipexole.

Analysis of variance (log values).

SD, standard deviation; IPD, idiopathic Parkinson’s disease; MMSE, Mini-Mental State Examination; BMI, body mass index; PD, Parkinson’s disease; NREM, non-rapid eye movement; REM, rapid eye movement.